<?xml version="1.0" encoding="ISO-8859-1"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><atom:link href="http://www.theheart.org/rssfeed.do" rel="self" type="application/rss+xml" /><title>theHeart.org - Meeting coverage</title><link>http://www.theheart.org/condition/meeting-coverage.do</link><description></description><image> <url>http://www.theheart.org/documents/sitestructure/resources/images/maintho_logo_rss.png</url> <title>theHeart.org- Meeting coverage</title> <link>http://www.theheart.org/condition/meeting-coverage.do</link></image>    <item>    <link>http://www.theheart.org/article/1017689.do</link>    <title>Advocates build support for Canadian Heart Health Strategy in a difficult environment</title>    <description>    <![CDATA[ Supporters of the Canadian Heart Health Strategy and Action Plan continue to solicit support from physicians and the public for a comprehensive strategy for improving Canadian's heart health at both the provincial and federal level. ]]>    </description>    <pubDate>    Mon, 02 Nov 2009 11:15:59 EST    </pubDate>    <guid>http://www.theheart.org/article/1017689.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1017525.do</link>    <title>Blood type of pig may be factor in longevity of porcine replacement heart valves</title>    <description>    <![CDATA[ Researchers in Ottawa find that the longevity of porcine replacement heart valves may depend partly on whether the blood type of the patient matches the blood type of the valve's "original owner." ]]>    </description>    <pubDate>    Fri, 30 Oct 2009 16:45:00 EDT    </pubDate>    <guid>http://www.theheart.org/article/1017525.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1017153.do</link>    <title>Combination drugs for weight loss</title>    <description>    <![CDATA[ Two studies presented this week have shown positive effects on weight loss using a combination of agents. ]]>    </description>    <pubDate>    Thu, 29 Oct 2009 15:30:33 EDT    </pubDate>    <guid>http://www.theheart.org/article/1017153.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1017037.do</link>    <title>Benefits of targeted lead placement with CRT devices supported by long-term mortality data</title>    <description>    <![CDATA[ An additional year of data from the INCREMENTAL study showed that echo-targeted LV lead positioning increased the likelihood of a response to device therapy by about 40% over standard lead placement. But does that difference translate into better long-term outcomes for the patient? ]]>    </description>    <pubDate>    Thu, 29 Oct 2009 15:00:55 EDT    </pubDate>    <guid>http://www.theheart.org/article/1017037.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1016975.do</link>    <title>First trial of viral-derived protein agent shows promise as anti-inflammatory ACS therapy</title>    <description>    <![CDATA[ Inflammatory responses contribute to coronary plaque rupture, thrombosis, and vascular occlusion. Some viruses have proteins that interfere with these inflammatory responses. Researchers have identified a viral-derived protein that may eventually be an anti-inflammatory treatment for coronary syndromes. ]]>    </description>    <pubDate>    Thu, 29 Oct 2009 11:45:16 EDT    </pubDate>    <guid>http://www.theheart.org/article/1016975.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1016067.do</link>    <title>Underutilization of ICDs in CABG patients is worst in women and elderly, Halifax study shows</title>    <description>    <![CDATA[ Only 101 of 1169 post-bypass-surgery patients eligible for an ICD got one over a 13-year period in Nova Scotia.  ]]>    </description>    <pubDate>    Wed, 28 Oct 2009 16:45:37 EDT    </pubDate>    <guid>http://www.theheart.org/article/1016067.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1016657.do</link>    <title>Schizophrenia plus diabetes linked with higher CAD yet lower revascularization rates</title>    <description>    <![CDATA[ Individuals with schizophrenia and diabetes&#151;as opposed to diabetes only&#151;have a greater risk of CAD but a smaller likelihood of receiving CABG or PCI, a large cohort study suggests. ]]>    </description>    <pubDate>    Wed, 28 Oct 2009 16:30:56 EDT    </pubDate>    <guid>http://www.theheart.org/article/1016657.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1016585.do</link>    <title>Bariatric surgery fails to reduce risk of MI long term</title>    <description>    <![CDATA[ After a median follow-up of 12 years, MI rates were essentially the same among those treated with surgery and those who received conventional care for weight loss. ]]>    </description>    <pubDate>    Wed, 28 Oct 2009 14:30:14 EDT    </pubDate>    <guid>http://www.theheart.org/article/1016585.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1016353.do</link>    <title>Lorcaserin passes weight-loss and valvular hurdles in BLOSSOM study</title>    <description>    <![CDATA[ Among overweight patients, including those with preexisting echocardiographic valvulopathy, the average weight loss was approximately 5 kg with lorcaserin. Importantly, there were no concerns raised about new or worsening cardiac valve problems with the 5HT2C-receptor agonist. ]]>    </description>    <pubDate>    Tue, 27 Oct 2009 16:15:27 EDT    </pubDate>    <guid>http://www.theheart.org/article/1016353.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1016171.do</link>    <title>Contrary to common belief, women feel same heart-attack symptoms as men</title>    <description>    <![CDATA[ Women and men have the same rates of chest pain and other classic symptoms during ACS, although women are more likely to experience some other symptoms such as jaw and neck pain. ]]>    </description>    <pubDate>    Tue, 27 Oct 2009 14:30:23 EDT    </pubDate>    <guid>http://www.theheart.org/article/1016171.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1015993.do</link>    <title>Blood products should be used conservatively in heart-surgery patients, trial shows</title>    <description>    <![CDATA[ Administration of blood products to stable patients post-cardiac surgery increases their risk of death, renal failure, and sepsis, according to new research. ]]>    </description>    <pubDate>    Tue, 27 Oct 2009 12:15:25 EDT    </pubDate>    <guid>http://www.theheart.org/article/1015993.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1015749.do</link>    <title>ACCORD update: "One size fits all" may not be best glucose-lowering strategy </title>    <description>    <![CDATA[ While post hoc analyses of ACCORD data suggest there are subgroups of diabetic patients who may not benefit from an aggressive glucose-lowering approach, similar analyses with ADVANCE data did not identify subgroup differences.    ]]>    </description>    <pubDate>    Tue, 27 Oct 2009 10:00:02 EDT    </pubDate>    <guid>http://www.theheart.org/article/1015749.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1015787.do</link>    <title>Experts weigh in on calorie lists on menus, despite "mixed" science</title>    <description>    <![CDATA[ Results showing that people eat less when they know how many calories are in that Big Mac are mixed, but experts say that menu labeling provides only upside, with no public-health cost, and that over time results will show the information to have a positive effect on obesity rates in the US. ]]>    </description>    <pubDate>    Mon, 26 Oct 2009 16:45:21 EDT    </pubDate>    <guid>http://www.theheart.org/article/1015787.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1015367.do</link>    <title>Less exposure to cardiovascular risk factors with intensive diabetes intervention: Look AHEAD </title>    <description>    <![CDATA[ Intensive lifestyle intervention in the management of diabetes produces sustained weight loss and improvements in fitness, as well as improvements in glycemic control, systolic blood pressure, and HDL-cholesterol levels. ]]>    </description>    <pubDate>    Mon, 26 Oct 2009 10:00:00 EDT    </pubDate>    <guid>http://www.theheart.org/article/1015367.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1014997.do</link>    <title>Glucose lowering in type 2 diabetes to prevent CVD remains controversial but still important</title>    <description>    <![CDATA[ Although the case for intensive glucose lowering in diabetic patients to prevent CVD is not straightforward, glucose control is still important for other reasons, and blood pressure and lipid control should not be neglected, according to debaters at a diabetes meeting.   ]]>    </description>    <pubDate>    Thu, 22 Oct 2009 14:45:51 EDT    </pubDate>    <guid>http://www.theheart.org/article/1014997.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1014607.do</link>    <title>Current risk equations may overestimate CVD risk in diabetic patients </title>    <description>    <![CDATA[ Researchers using different international databases report that the Framingham and UKPDS risk equations overestimate the probability of CV events in diabetic patients.  ]]>    </description>    <pubDate>    Wed, 21 Oct 2009 10:00:31 EDT    </pubDate>    <guid>http://www.theheart.org/article/1014607.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1014307.do</link>    <title>Thiazolidinediones have a role for appropriate diabetic patients</title>    <description>    <![CDATA[ After 10 years of clinical use of TZDs, "we are still at the beginning," and randomized controlled trials shed light on their use in appropriate diabetic patients, speakers at a diabetes symposium reported.  ]]>    </description>    <pubDate>    Tue, 20 Oct 2009 12:45:38 EDT    </pubDate>    <guid>http://www.theheart.org/article/1014307.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1012275.do</link>    <title>Target HbA1c levels still the subject of much debate, but tailored therapy should be the aim </title>    <description>    <![CDATA[ Diabetologists are trying to tease out the best message to convey when it comes to target HbA<sub>1c</sub> levels for primary-care physicians and other nonspecialists who might be treating patients with type 2 diabetes.  ]]>    </description>    <pubDate>    Fri, 09 Oct 2009 16:45:25 EDT    </pubDate>    <guid>http://www.theheart.org/article/1012275.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1011331.do</link>    <title>Experts debate bariatric surgery as a cure for diabetes </title>    <description>    <![CDATA[ Under the some-say-misguided term "metabolic" surgery, gastric bypass is now being used in some instances to treat diabetics who are not considered morbidly obese. Experts say the mostly circumstantial evidence on this is intriguing, but prospective data are desperately needed in this group of patients. ]]>    </description>    <pubDate>    Thu, 08 Oct 2009 13:15:54 EDT    </pubDate>    <guid>http://www.theheart.org/article/1011331.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1010567.do</link>    <title>Hypoglycemia associated with increased risk of MI among US veterans with diabetes </title>    <description>    <![CDATA[ Close attention should be paid to diabetes patients who experience an episode of hypoglycemia, because a new case-control study suggests a 65% increased risk of MI in the immediate two-week aftermath of such an event. Doctors should tailor diabetes therapies to minimize the risk of hypoglycemia occurring, say the researchers.  ]]>    </description>    <pubDate>    Mon, 05 Oct 2009 13:45:19 EDT    </pubDate>    <guid>http://www.theheart.org/article/1010567.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1010255.do</link>    <title>Insulin glargine and cancer: Association, no causal link </title>    <description>    <![CDATA[ That was the conclusion of a recent panel of experts, perhaps alleviating concerns raised by several recent studies.   ]]>    </description>    <pubDate>    Fri, 02 Oct 2009 15:00:18 EDT    </pubDate>    <guid>http://www.theheart.org/article/1010255.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1009621.do</link>    <title>Time to act: Cardiologists, diabetes docs, and psychiatrists urged to work together to tackle CVD in the mentally ill </title>    <description>    <![CDATA[ Doctors from across the specialties of cardiology, diabetes, and psychiatry are being urged to collaborate to improve care for the mentally ill, who are more likely to die from cardiovascular disease than any other cause. ]]>    </description>    <pubDate>    Wed, 30 Sep 2009 14:00:04 EDT    </pubDate>    <guid>http://www.theheart.org/article/1009621.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1009297.do</link>    <title>Kissing-balloon dilatation of side branch not needed with one-stent bifurcation approach</title>    <description>    <![CDATA[ With the one-stent technique for the treatment of bifurcation lesions, the use of routine kissing-balloon dilatation of the side branch does not improve six-month clinical outcomes. ]]>    </description>    <pubDate>    Tue, 29 Sep 2009 16:15:30 EDT    </pubDate>    <guid>http://www.theheart.org/article/1009297.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1009035.do</link>    <title>BCIS-1 trial: "Bailout" intra-aortic balloon pump beats elective use in low EF/high-risk patients</title>    <description>    <![CDATA[ The study provides an important answer to a question that has divided some interventionalists. Those who "swear" by IABP use for all high-risk, low-EF patients should rethink their practice. In hypotensive patients and those with cardiogenic shock, IABPs play a key role.  ]]>    </description>    <pubDate>    Tue, 29 Sep 2009 10:45:47 EDT    </pubDate>    <guid>http://www.theheart.org/article/1009035.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1008965.do</link>    <title>FAUST: Ultrasound guidance improves femoral access in cases of high bifurcation, reduces risk of complication</title>    <description>    <![CDATA[ <b><i>CORRECTED </i></b><i>// </i>A study has found that although ultrasound imaging doesn't seem to improve upon the overall success rate of fluoroscopy-assisted femoral-access PCI, it does seem to facilitate the procedure, reducing the risk of access complications by 59% and doubling the first-pass success rate. ]]>    </description>    <pubDate>    Tue, 29 Sep 2009 09:45:25 EDT    </pubDate>    <guid>http://www.theheart.org/article/1008965.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1008623.do</link>    <title>CHARISMA Genomics Substudy links loss-of-function allele and bleeding</title>    <description>    <![CDATA[ Patients who are homozygous for the CYP2C19*2 allele are at increased risk of ischemia but less likely to bleed. Routine genotyping for the variant still isn't recommended. ]]>    </description>    <pubDate>    Mon, 28 Sep 2009 14:15:11 EDT    </pubDate>    <guid>http://www.theheart.org/article/1008623.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1008155.do</link>    <title>Reduced bleeding and comparable stent thrombosis with DES and bare-metal stents: HORIZONS-AMI at two years</title>    <description>    <![CDATA[ Two-year data showed significant reductions in bleeding and cardiac mortality in patients treated with bivalirudin when compared with those treated with heparin plus a GP IIb/IIIa inhibitor. In the stent arm of the trial, researchers showed that stent thrombosis rates were equivalent between DES and bare-metal stents, although both rates were high, at 4.1%.  ]]>    </description>    <pubDate>    Fri, 25 Sep 2009 17:55:17 EDT    </pubDate>    <guid>http://www.theheart.org/article/1008155.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1008053.do</link>    <title>PLATO-Invasive: Impressive ticagrelor results mirror overall trial findings </title>    <description>    <![CDATA[ The prespecified subset analysis helps clarify the performance of the drug in patients managed invasively, including adding new insights into its benefits over both the 300-mg and 600-mg loading doses of clopidogrel.  ]]>    </description>    <pubDate>    Fri, 25 Sep 2009 17:30:21 EDT    </pubDate>    <guid>http://www.theheart.org/article/1008053.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1007873.do</link>    <title>PROSPECT: Vulnerable lesions lead to unstable angina rather than MI or death</title>    <description>    <![CDATA[ After successful PCI, 20% of patients go on to have a MACE at three years and 12% of patients develop events from nonculprit lesions. PROSPECT investigators say, however, that events from these nonculprit lesions are more likely to be unstable angina or progressive angina, rather than harder events such as MI or cardiac death. ]]>    </description>    <pubDate>    Fri, 25 Sep 2009 14:15:11 EDT    </pubDate>    <guid>http://www.theheart.org/article/1007873.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1007461.do</link>    <title>BNP-boosting gene variant hints at possible screening, cardioprotective roles  </title>    <description>    <![CDATA[ A single-nucleotide polymorphism associated with chronically raised natriuretic-peptide levels is common enough to potentially influence interpretation of BNP and NT-proBNP assays under some circumstances, researchers say; there is increasing evidence that the gene variant may enhance survival in some patient groups. ]]>    </description>    <pubDate>    Fri, 25 Sep 2009 10:45:02 EDT    </pubDate>    <guid>http://www.theheart.org/article/1007461.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1007305.do</link>    <title>COMPARE: "Real-world" randomized trial favors Xience V over Taxus Liberté </title>    <description>    <![CDATA[ COMPARE is the second of two large randomized controlled trials comparing a Taxus stent with Xience V to show a clear benefit of the newer stent. ]]>    </description>    <pubDate>    Fri, 25 Sep 2009 08:30:19 EDT    </pubDate>    <guid>http://www.theheart.org/article/1007305.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1007269.do</link>    <title>Doubling dose of clopidogrel benefits STEMI patients without risk of bleeding</title>    <description>    <![CDATA[ Doubling the dose of clopidogrel reduced the risk of MI and stent thrombosis in STEMI patients without increasing the risk of bleeding. The benefit extended to patients who received a bare-metal stent or a drug-eluting stent. ]]>    </description>    <pubDate>    Thu, 24 Sep 2009 17:45:49 EDT    </pubDate>    <guid>http://www.theheart.org/article/1007269.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1007145.do</link>    <title>COGENT: No CV events but significant GI benefits of PPI omeprazole</title>    <description>    <![CDATA[ The randomized controlled trial results should put a stop to alarmist headlines about PPIs blunting efficacy of antiplatelet drugs, experts say. By withholding PPIs, physicians are doing more harm than good, the results suggest. ]]>    </description>    <pubDate>    Thu, 24 Sep 2009 16:30:07 EDT    </pubDate>    <guid>http://www.theheart.org/article/1007145.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1007049.do</link>    <title>FAME lives on: FFR results durable at two years</title>    <description>    <![CDATA[ The past few cardiology meetings have included data on the FAME study, and TCT 2009 was no exception. Investigators showed that the one-year and 18-month results were durable out to two years, although some researchers would like to see the study replicated to conclusively prove the added value of fractional flow reserve testing. ]]>    </description>    <pubDate>    Thu, 24 Sep 2009 14:45:38 EDT    </pubDate>    <guid>http://www.theheart.org/article/1007049.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1006629.do</link>    <title>SIRTAX LATE: No differences in MACE for first-generation stents at five years</title>    <description>    <![CDATA[ After one year, Cypher had lower rates of death, MI, or repeat PCIs than Taxus in the SIRTAX trial. But four years later, investigators say all differences between the two have disappeared, in part due to more late "catch-up" with the Cypher.  ]]>    </description>    <pubDate>    Thu, 24 Sep 2009 08:30:17 EDT    </pubDate>    <guid>http://www.theheart.org/article/1006629.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1006595.do</link>    <title>Stent sandwich: First-generation stents equal for Cypher in-stent restenosis</title>    <description>    <![CDATA[ Late lumen loss at one year, the primary end point, was equivalent between the Cypher and Taxus stent at one year among patients with restenosis after initial treatment with the Cypher stent.  ]]>    </description>    <pubDate>    Thu, 24 Sep 2009 07:45:13 EDT    </pubDate>    <guid>http://www.theheart.org/article/1006595.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1006453.do</link>    <title>SPIRIT IV: Xience V trumps Taxus for clinically driven end points, although diabetic questions linger</title>    <description>    <![CDATA[ <b><i>UPDATED</i></b> // Rates of target lesion failure were significantly lower for the everolimus-eluting Xience V stent for the trial as a whole. In diabetic patients only, however, no differences were seen between the two stents. ]]>    </description>    <pubDate>    Wed, 23 Sep 2009 16:15:24 EDT    </pubDate>    <guid>http://www.theheart.org/article/1006453.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1006177.do</link>    <title>Should patients go directly to a PCI-capable hospital? Two studies, different results</title>    <description>    <![CDATA[ One trial showed that despite a mean treatment delay of 67 minutes, STEMI patients undergoing primary PCI taken first to an emergency department before transfer had equivalent rates of major adverse cardiac events when compared with those who presented directly to a PCI facility. A smaller study showed that taking patients directly to the cardiac center resulted in significantly better survival when compared with patients who were transported to an emergency department. ]]>    </description>    <pubDate>    Wed, 23 Sep 2009 10:45:51 EDT    </pubDate>    <guid>http://www.theheart.org/article/1006177.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1006131.do</link>    <title>Changing PARTNER: Program tweaks overshadow updates from transcatheter-valve studies</title>    <description>    <![CDATA[ A packed session of interventionalists eager to hear more about long-term safety and efficacy were caught off-guard by news that a new co-primary end point has been added to cohort B.  ]]>    </description>    <pubDate>    Wed, 23 Sep 2009 09:15:00 EDT    </pubDate>    <guid>http://www.theheart.org/article/1006131.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1006071.do</link>    <title>Senators question Dr Martin Leon's financial links to industry</title>    <description>    <![CDATA[ <b><i>UPDATED</i></b> // The letter, from Sens Herb Kohl and Charles Grassley, states that Leon did not fully disclose much of the money he has received from outside companies.  ]]>    </description>    <pubDate>    Tue, 22 Sep 2009 17:15:30 EDT    </pubDate>    <guid>http://www.theheart.org/article/1006071.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1005711.do</link>    <title>Mixed start to planned MARVEL trial of post-MI autologous skeletal-myoblast therapy</title>    <description>    <![CDATA[ A pilot analysis suggests the cell therapy can improve functional capacity, but amiodarone may be needed to prevent ventricular arrhythmias; its investigators say they plan to switch gears on the remainder of the study. ]]>    </description>    <pubDate>    Tue, 22 Sep 2009 14:00:42 EDT    </pubDate>    <guid>http://www.theheart.org/article/1005711.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1005755.do</link>    <title>Should left main PCI be a class IIa indication?</title>    <description>    <![CDATA[ TCT 2009 kicked off with a discussion on revascularization strategies for left main PCI. Interventionalist Dr Paul Teirstein argues the data are sufficient for left main PCI to be a class IIa indication, upgrading it from the current class III recommendation, but surgeon Dr David Taggart says that CABG is still the preferred revascularization option in the majority of left main patients. ]]>    </description>    <pubDate>    Tue, 22 Sep 2009 13:15:44 EDT    </pubDate>    <guid>http://www.theheart.org/article/1005755.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1005627.do</link>    <title>Three-year SPIRIT III results show enduring edge for Xience V over Taxus </title>    <description>    <![CDATA[ Three-year target vessel failure remained statistically lower for the everolimus-eluting Xience V stent (which is also marketed as the Promus) than for the paclitaxel-eluting Taxus stent.  ]]>    </description>    <pubDate>    Tue, 22 Sep 2009 11:45:00 EDT    </pubDate>    <guid>http://www.theheart.org/article/1005627.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1005381.do</link>    <title>ENDEAVOR IV: Revascularization rates similar for Endeavor and Taxus at three years, with Endeavor "pulling ahead" for safety </title>    <description>    <![CDATA[ Rates of cardiac death and MI actually statistically favor the Endeavor stent at three years, new data show. Stent thrombosis occurred just once after one year for Endeavor, as compared with 11 cases after the one-year mark in the Taxus-treated patients. ]]>    </description>    <pubDate>    Tue, 22 Sep 2009 09:45:47 EDT    </pubDate>    <guid>http://www.theheart.org/article/1005381.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1004981.do</link>    <title>Added to diuretics, low-dose dopamine renoprotective in small acute-HF trial</title>    <description>    <![CDATA[ Better late than never in the age of evidence-based medicine, a randomized test of an established strategy might have confirmed the value of adding dopamine to loop diuretics to allow the latter at reduced, less kidney-damaging dosages.  ]]>    </description>    <pubDate>    Mon, 21 Sep 2009 12:30:00 EDT    </pubDate>    <guid>http://www.theheart.org/article/1004981.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1004117.do</link>    <title>Coumarin derivatives affect clopidogrel action</title>    <description>    <![CDATA[ Another interaction that may affect the response to clopidogrel has been reported, this time with the coumarin derivative phenprocoumon, an anticoagulant commonly used in Europe.  ]]>    </description>    <pubDate>    Thu, 17 Sep 2009 12:00:47 EDT    </pubDate>    <guid>http://www.theheart.org/article/1004117.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1003939.do</link>    <title>Physician, teach thyself: IMPROVE-HF initiative boosts use of evidence-based outpatient care</title>    <description>    <![CDATA[ The two-year prospective registry-based study of a performance-improvement initiative's effectiveness saw significant jumps, &gt;70% in some cases, in the appropriate use of six out of seven measured evidence-based treatments for patients with chronic heart failure. ]]>    </description>    <pubDate>    Wed, 16 Sep 2009 17:45:55 EDT    </pubDate>    <guid>http://www.theheart.org/article/1003939.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1003313.do</link>    <title>FAST enough? Intrathoracic monitor bests weight gain in predicting worsening heart failure</title>    <description>    <![CDATA[ Can an intrathoracic fluid-status monitor, added to an already-indicated ICD or CRT-D device in patients with heart failure, serve as the decompensation early-warning system now provided&#151;unreliably but as recommended in the guidelines&#151;by the bathroom scale?   ]]>    </description>    <pubDate>    Tue, 15 Sep 2009 14:30:51 EDT    </pubDate>    <guid>http://www.theheart.org/article/1003313.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1003065.do</link>    <title>Conflicts of interest affect best practices in both industry-funded and non-industry-funded trials </title>    <description>    <![CDATA[ Clinicians and researchers need to be more aware before signing on to studies about what potential conflicts might arise with the sponsor and set the ground rules for such areas as access to data, manuscript preparation, and right to publish.  ]]>    </description>    <pubDate>    Tue, 15 Sep 2009 12:00:19 EDT    </pubDate>    <guid>http://www.theheart.org/article/1003065.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1002895.do</link>    <title>Who should get CRT? Resynchronization benefits seen in heart failure with LVEF &gt;35%</title>    <description>    <![CDATA[ Heart-failure patients with ejection fractions &gt;35% aren't necessarily excluded from the clinical and reverse-remodeling benefits of cardiac resynchronization therapy, suggests yet another study questioning the limits of CRT's current eligibility criteria. ]]>    </description>    <pubDate>    Mon, 14 Sep 2009 17:15:00 EDT    </pubDate>    <guid>http://www.theheart.org/article/1002895.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1002379.do</link>    <title>Sponsorship of med-school textbooks in Denmark exposes vulnerable minds to commercial bias</title>    <description>    <![CDATA[ Results of a new survey showed that a surprising 15% of textbooks had one or more drug or device sponsors and, in two cases, those sponsors had tried to influence the content of the textbooks. ]]>    </description>    <pubDate>    Mon, 14 Sep 2009 11:45:00 EDT    </pubDate>    <guid>http://www.theheart.org/article/1002379.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1002389.do</link>    <title>Spin not uncommon in negative RCTs, study shows</title>    <description>    <![CDATA[ French researchers who systematically quantified the prevalence of spin across 72 negative randomized controlled trials say half of the studies put a positive spin on the negative findings in the conclusion sections of the papers.  ]]>    </description>    <pubDate>    Mon, 14 Sep 2009 11:30:00 EDT    </pubDate>    <guid>http://www.theheart.org/article/1002389.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1002305.do</link>    <title>B-CONVINCED: Maintain beta blockers during acute heart-failure management </title>    <description>    <![CDATA[ Short-term outcomes are the same whether beta blockers are continued or withheld at hospitalization for acute decompensated heart failure, and there are good reasons to continue them, according to researchers.  ]]>    </description>    <pubDate>    Mon, 14 Sep 2009 10:30:00 EDT    </pubDate>    <guid>http://www.theheart.org/article/1002305.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1002261.do</link>    <title>Nationwide smoking ban cuts incidence of acute coronary syndrome in nonsmokers</title>    <description>    <![CDATA[ A smoking ban in public places throughout Iceland resulted in a 21% reduction in ACS among nonsmoking men. ]]>    </description>    <pubDate>    Mon, 14 Sep 2009 09:45:00 EDT    </pubDate>    <guid>http://www.theheart.org/article/1002261.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1001867.do</link>    <title>Ghost authorship on the wane, but guest authorship still common </title>    <description>    <![CDATA[ <b><i>UPDATED</i></b> // Compared with a 1996 survey by <i>JAMA</i> editors, a 2008 survey indicates that the practice of having ghost writers pen papers, then not appear as authors, is down to 8%, from 12% in 1996. The practice of inviting a prominent name to appear in the list of authors, without requiring that person to contribute to the research, has held steady at roughly 20%.  ]]>    </description>    <pubDate>    Fri, 11 Sep 2009 11:00:38 EDT    </pubDate>    <guid>http://www.theheart.org/article/1001867.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1001517.do</link>    <title>Ivabradine BEAUTIFUL in subset of patients with angina and heart rates &gt;70 bpm</title>    <description>    <![CDATA[ Ivabradine may reduce major cardiovascular events in patients with stable CAD and LV dysfunction who present with limiting angina, BEAUTIFUL investigators say in a post hoc analysis. ]]>    </description>    <pubDate>    Thu, 10 Sep 2009 16:00:11 EDT    </pubDate>    <guid>http://www.theheart.org/article/1001517.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1001103.do</link>    <title>Implantable ECG loop recorder differentiates between syncope and epilepsy</title>    <description>    <![CDATA[ Is it syncope? Or is it epilepsy? When there's doubt, an implantable ECG loop recorder can help make the correct diagnosis. ]]>    </description>    <pubDate>    Wed, 09 Sep 2009 11:00:16 EDT    </pubDate>    <guid>http://www.theheart.org/article/1001103.do</guid>    </item>    <item>    <link>http://www.theheart.org/article/1001063.do</link>    <title>New ESC guidelines on infective endocarditis </title>    <description>    <![CDATA[ The ESC issues new recommendations on the prevention, diagnosis, and treatment of infective endocarditis&#151;"an old but changing disease." The guidance with respect to antibiotic prophylaxis is similar to US advice, experts say. ]]>    </description>    <pubDate>    Wed, 09 Sep 2009 09:45:03 EDT    </pubDate>    <guid>http://www.theheart.org/article/1001063.do</guid>    </item></channel></rss>